Inmune Bio, Inc.

INmune Bio is a clinical-stage biotechnology company developing immunology-focused therapeutics designed to reprogram patients' innate immune systems. The company's pipeline targets hematologic malignancies, solid tumors, and chronic inflammatory conditions. Its development programs include INKmune, currently in Phase 1 testing for high-risk myelodysplastic syndrome, and INB03, in Phase II development for breast cancer treatment. The company also holds rights to XPro1595, being evaluated for Alzheimer's disease and treatment-resistant depression, and CORDstrom, a cell suspension therapy comprising allogeneic human umbilical cord mesenchymal stem cells for intravenous or injection-based administration.

The company operates through licensing partnerships with established entities including Xencor, Immune Ventures, and the University of Pittsburgh, which provide access to underlying intellectual property and research capabilities. As a clinical-stage entity without disclosed revenue, INmune Bio currently generates income primarily through its licensing arrangements rather than product commercialization.

Based in Boca Raton, Florida, INmune Bio operates with a lean structure of 13 full-time employees. The company maintains its primary operations in the United States and is incorporated in Nevada with listing on the Nasdaq exchange.